Literature DB >> 20053749

Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Joseph P Nkolola1, Hanqin Peng, Ethan C Settembre, Michael Freeman, Lauren E Grandpre, Colleen Devoy, Diana M Lynch, Annalena La Porte, Nathaniel L Simmons, Ritu Bradley, David C Montefiori, Michael S Seaman, Bing Chen, Dan H Barouch.   

Abstract

The native envelope (Env) spike on the surface of human immunodeficiency virus type 1 (HIV-1) is trimeric, and thus trimeric Env vaccine immunogens are currently being explored in preclinical immunogenicity studies. Key challenges have included the production and purification of biochemically homogeneous and stable trimers and the evaluation of these immunogens utilizing standardized virus panels for neutralization assays. Here we report the binding and neutralizing antibody (NAb) responses elicited by clade A (92UG037.8) and clade C (CZA97.012) Env gp140 trimer immunogens in guinea pigs. These trimers have been selected and engineered for optimal biochemical stability and have defined antigenic properties. Purified gp140 trimers with Ribi adjuvant elicited potent, cross-clade NAb responses against tier 1 viruses as well as detectable but low-titer NAb responses against select tier 2 viruses from clades A, B, and C. In particular, the clade C trimer elicited NAbs that neutralized 27%, 20%, and 47% of tier 2 viruses from clades A, B, and C, respectively. Heterologous DNA prime, protein boost as well as DNA prime, recombinant adenovirus boost regimens expressing these antigens, however, did not result in an increased magnitude or breadth of NAb responses in this system. These data demonstrate the immunogenicity of stable, homogeneous clade A and clade C gp140 trimers and exemplify the utility of standardized tier 1 and tier 2 virus panels for assessing the NAb responses of candidate HIV-1 Env immunogens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053749      PMCID: PMC2838122          DOI: 10.1128/JVI.02252-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160.

Authors:  B Chen; G Zhou; M Kim; Y Chishti; R E Hussey; B Ely; J J Skehel; E L Reinherz; S C Harrison; D C Wiley
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

2.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

3.  High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.

Authors:  E W Carrow; L K Vujcic; W L Glass; K B Seamon; S C Rastogi; R M Hendry; R Boulos; N Nzila; G V Quinnan
Journal:  AIDS Res Hum Retroviruses       Date:  1991-10       Impact factor: 2.205

4.  Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer.

Authors:  C W Zhang; Y Chishti; R E Hussey; E L Reinherz
Journal:  J Biol Chem       Date:  2001-08-20       Impact factor: 5.157

5.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 6.  The HIV Env-mediated fusion reaction.

Authors:  Stephen A Gallo; Catherine M Finnegan; Mathias Viard; Yossef Raviv; Antony Dimitrov; Satinder S Rawat; Anu Puri; Stewart Durell; Robert Blumenthal
Journal:  Biochim Biophys Acta       Date:  2003-07-11

7.  The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.

Authors:  T Vogel; R Kurth; S Norley
Journal:  J Immunol       Date:  1994-08-15       Impact factor: 5.422

8.  Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

Authors:  P L Nara; W G Robey; S W Pyle; W C Hatch; N M Dunlop; J W Bess; J C Kelliher; L O Arthur; P J Fischinger
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Comparison of the immune response to recombinant gp120 in humans and chimpanzees.

Authors:  P W Berman; D J Eastman; D M Wilkes; G R Nakamura; T J Gregory; D Schwartz; G Gorse; R Belshe; M L Clements; R A Byrn
Journal:  AIDS       Date:  1994-05       Impact factor: 4.177

10.  Studies on the immunogenicity of Chinese hamster ovary cell-derived recombinant gp120 (HIV-1IIIB).

Authors:  M Page; K H Mills; G C Schild; C Ling; V Patel; A McKnight; A L Barnard; P Dilger; R Thorpe
Journal:  Vaccine       Date:  1991-01       Impact factor: 3.641

View more
  65 in total

1.  Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Authors:  Marit Kramski; Rob J Center; Adam K Wheatley; Jonathan C Jacobson; Marina R Alexander; Grant Rawlin; Damian F J Purcell
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site.

Authors:  Yu Feng; Krisha McKee; Karen Tran; Sijy O'Dell; Stephen D Schmidt; Adhuna Phogat; Mattias N Forsell; Gunilla B Karlsson Hedestam; John R Mascola; Richard T Wyatt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

3.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Authors:  James M Kovacs; Joseph P Nkolola; Hanqin Peng; Ann Cheung; James Perry; Caroline A Miller; Michael S Seaman; Dan H Barouch; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

4.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

5.  A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Authors:  Christine A Bricault; James M Kovacs; Joseph P Nkolola; Karina Yusim; Elena E Giorgi; Jennifer L Shields; James Perry; Christy L Lavine; Ann Cheung; Katharine Ellingson-Strouss; Cecelia Rademeyer; Glenda E Gray; Carolyn Williamson; Leonidas Stamatatos; Michael S Seaman; Bette T Korber; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

6.  DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.

Authors:  Veena Menon; Victor I Ayala; Sneha P Rangaswamy; Irene Kalisz; Stephen Whitney; Lindsey Galmin; Asma Ashraf; Celia LaBranche; David Montefiori; Nikolai Petrovsky; Vaniambadi S Kalyanaraman; Ranajit Pal
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

7.  Immunosilencing a highly immunogenic protein trimerization domain.

Authors:  Kwinten Sliepen; Thijs van Montfort; Mark Melchers; Gözde Isik; Rogier W Sanders
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

8.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

9.  Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Ann Cheung; James R Perry; Darrick Carter; Steve Reed; Hanneke Schuitemaker; Maria Grazia Pau; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  Vaccine       Date:  2014-02-18       Impact factor: 3.641

10.  Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.

Authors:  Douglas H Smith; Peggy Winters-Digiacinto; Misrach Mitiku; Sara O'Rourke; Faruk Sinangil; Terri Wrin; David C Montefiori; Phillip W Berman
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.